- This event has passed.
IMNM, Clinical Trials, & COVID-19
September 15, 2020 @ 3:00 pm - 4:00 pm EDT
Free
September 2020 Myositis Awareness
High Fives from the Heart: #MyositisLIFE in a Pandemic World
Keeping you informed during the COVID-19 pandemic
Register to join us for
IMNM, Clinical Trials, & COVID-19
with Dr. Andrew Mammen and Dr. Petra Duda
Tuesday, September 15, 2020, at 3:00 PM Eastern Time
Webinar Details
Join us for an interesting and engaging discussion around IMNM, clinical trials, and COVID-19. Special guests: Dr. Andrew Mammen from the National Institutes of Health (NIH) and Dr. Petra Duda from UCB.
Learn more about immune-mediated necrotizing myopathy (IMNM) and the phase 2 clinical trial of Zilucoplan by UCB.
About joining this webinar
REGISTRATION IS REQUIRED. Click the Register button above to get started. After registration, you will receive an email containing all information needed to join the webinar at the scheduled time and date.
Be sure to check your spam and junk folders if you do not see the email.
About Dr. Mammen
Andrew Mammen, M.D., Ph.D., joined NIAMS as Muscle Disease Unit Leader in the Laboratory of Muscle Stem Cells and Gene Regulation in 2014. He obtained his medical degree and Ph.D. in neuroscience at Johns Hopkins in 2000, where he subsequently completed his medicine internship, neurology residency, and neuromuscular fellowship. Prior to his appointment at NIH, he was Associate Professor of Neurology and Medicine at the Johns Hopkins University School of Medicine. He co-founded the Johns Hopkins Myositis Center in 2007, where he continues to see myositis patients as an adjunct faculty member. Dr. Mammen and his colleagues at Hopkins discovered a novel form of autoimmune myopathy associated with statin use and autoantibodies recognizing HMG-CoA reductase, the pharmacologic target of statins. In addition to clinical studies involving myositis patients, his current laboratory research interests include defining pathogenic mechanisms in the various forms of autoimmune myopathy and understanding the role of myositis autoantigens in muscle regeneration. (From NIH)
About Dr. Duda
Petra Duda leads the zilucoplan development at Ra Pharmaceuticals, including in immune-mediated necrotizing myopathy. In addition to her current work, Dr. Duda has extensive experience across all stages of clinical drug development in neurological diseases. Prior to joining UCB, Dr. Duda led clinical development teams at Ra Pharmaceuticals, Sarepta Therapeutics and Biogen Idec and supported Medical Affairs and Drug Safety at Boehringer Ingelheim. Dr. Duda also served as a Clinical Neurologist and Clinical Research Scientist at the University Hospitals in Basel, Switzerland, and as a postdoctoral fellow in Neuroimmunology at the Harvard Institutes of Medicine in Boston, MA. She is board certified in Neurology and Pharmaceutical Medicine and holds MD and PhD degrees in molecular biology and biochemistry from the University of Bern, Switzerland.
